research

During the 2014 Innovation Convention, organised by the European Commission on Tuesday, Barcelona was named the first European Capital of Innovation. The Catalan capital has prevailed over finalists Grenoble (France) and Groningen (the Netherlands) in a contest which also involved Paris, Espoo (Finland) and Malaga (Spain). The winning project highlights the predominant role of the city in promoting new technologies and bringing together government bodies and citizens, in order to enhance sustainable economic growth and improve the people’s welfare. The award is endowed with € 500,000 to promote innovation. Barcelona's Mayor, Xavier Trias, stated that new technologies in an urban environment have to "work towards improving people's everyday lives[…] or they will fail".

The profits of Catalan pharmaceutical company Grífols in 2013 grew by 34.6% over the previous year, reaching €345.6 million, as reported by the multinational to the Spanish Stock Exchange Regulation Authority (CNMV). The turnover of the company, based in Greater Barcelona, amounted to €2.75 billion, representing a 4.6% increase on 2012 figures. The geographical expansion of the pharmaceutical company has helped mitigating the effects of volatility in currencies, especially between the euro and the dollar. The Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) grew by 9.6% compared to 2012 and stood at €864.6 million, driven by an increase in the sales of plasma proteins and the optimization of the expenses for raw materials and manufacturing.

The Catalan Institute of Nanoscience and Nanotechnology (ICN2) has set up its new headquarters at the Universitat Autònoma de Barcelona (UAB) campus. The new faculties are located in a 6,000 square meter building with 40 laboratories, where scientific projects will be developed in different areas, from biomedicine to the development of everyday products such as paint or detergents.. This project is funded by both the Catalan and Spanish Governments and aims to make the centre a flagship in the European scientific field.

‘elBulli1846’, the ambitious initiative of acclaimed Chef Ferran Adrià, could well become a reality in March 2016 thanks to a €9 million investment made through the Catalan Chef’s foundation. The Catalan Government described such an initiative as “a national project”. ‘elBulli1846’ is named after the number of dishes created in the 3-Michelin-star El Bulli, which was awarded the world’s best restaurant on 5 occasions. Adrià’s new project is notably looking to establish a unique centre in the world for innovation, research, and training in the field of avant-garde cuisine. Besides, for 20 days a year, visitors will have access to ElBulli restaurant, with half of the available entrances awarded for free through a lottery. The centre will be located in the old restaurant’s venue in the Cap de Creus Natural Park (Costa Brava). 3,000 square metres will be added but built respecting the environment.

A clinical trial conducted in nine Catalan health care centres and published in the ‘British Medical Journal’ found that “in the case of mild respiratory infections such as acute bronchitis, there is a misuse of antibiotics, which is of no benefit to patients, and only helps increasing resistance to these drugs”. The study has been coordinated by the prestigious Vall d’Hebron Research Institute (VHIR). From 2010 to 2012, 416 patients, who showed several signs of acute bronchitis, were randomly assigned one of three different treatments. The main conclusion was that antibiotics, the most widely prescribed treatment for this type of illness, are ineffective. The study also showed that anti-inflammatory treatments increased in a minimal way the chances of ending coughs faster.

Referring to yesterday’s announcement, Carles Constante, the Director General for Regulation, Planning and Health Resources at the Catalan Ministry of Health, said that the Director of Barcelona’s Centre for Regenerative Medicine (CMRB), Juan Carlos Izpisúa had resigned due to the need for a more direct management. Constante explained that even though research centres now had a “high level of interconnection and ongoing dialogue”, they also needed “direction, management and a drive of energy within the centre itself, something that could be difficult to maintain from a distance”. Constante stressed that Izpisúa working from the United States for most of the time had been the main reason for him stepping down.

The Director of Barcelona’s Centre for Regenerative Medicine (CMRB), world-famous scientist Juan Carlos Izpisúa, resigned due to the lack of financial and political support from both Spanish and Catalan Governments. Such news was first published by Spanish newspaper ‘El País’ and then confirmed by sources in the research centre. Internationally, Izpisúa is considered to be one of the most esteemed and learned scientists in the field of stem cells. With the Director stepping down, the CMRB could well lose most of its current projects. Indeed, 18 of the 21 projects are the intellectual property of Izpisúa and might no longer be carried out in the Barcelona-based research centre if Izpisúa quit.

People who follow a Mediterranean diet enriched with extra virgin olive oil will reduce by 40% the risk of having diabetes, and by 18% if the diet is enriched with nuts. This is one of the main conclusions of a scientific study conducted by 18 research centres throughout Spain on 3,500 people. Jordi Salas-Salvadó, Director of this study, said that such results would change the usual perception of diabetes prevention. The Mediterranean diet is not solely efficient against diabetes. Indeed, the results showed that following such a diet also reduced by 30% the chances of contracting cardiovascular diseases.

ICTINEU 3, a scientific submersible designed and build in Catalonia, has entered the water for the very first time in a test dive near Barcelona. For over ten years, particular donations have helped construct this submarine that will be dedicated to “underwater exploration, scientific research and underwater intervention”. This first test was used to verify that all of the submarine’s systems could function underwater, and the next step will be a dive in seawater. ICTINEU 3 was named after the very first air independent and combustion engine driven submarine, ICTINEU 1, which was invented by Figueres’ engineer Narcís Monturiol and dived for the first time in the Catalan capital’s harbour.

The Catalan pharmaceutical company Grífols and Barcelona’s Alzheimer Treatment&Research Center of Fundació ACE – a family charity – have announced that they will run tests of a vaccine against this neurodegenerative illness from January 2014. It will target 365 Alzheimer’s patients at mild and moderate stages of the illness. The first investigation project that ACE’s centre will host is called Ambar. The 365 participants will be randomly divided into three treatment groups plus a fourth control group. The patients will come from 17 Spanish hospitals and 20 United States’ medical centres. From 1996, the ACE Foundation has evaluated more than 14,000 people, 47% of whom were diagnosed with Alzheimer’s. It has the largest bank of genetic data in Europe.

Biocat, the organisation responsible for coordinating and promoting the life sciences sector in Catalonia, presented the 2013 Biocat report in Barcelona. Since its creation in 2006, by the Catalan Government and the Barcelona City Council, Biocat has sought to consolidate the life sciences sector by bringing together researchers, companies and other professionals in the field of biotechnology and biomedecine from Catalonia and other countries in the world. With 65 % of its biotechnology, pharmaceutical and medical products sold on the international market, the Catalan ‘Bioregion’(biocluster) is amongst the leaders in the sector. The cluster is currently made of 512 companies, meaning twice as many as in 2000, 56 research centers dedicated to life sciences or related disciplines, 17 university hospitals and 11 universities offering training in biosciences. It also relies on numerous other technology poles. This year’s report stressed the significant increase in private funding for the Catalan BioRegion over the last 4 years (€ 5.7 million to € 25.6 million) while highlighting the drop in public aid.

Doctor Joan Massagué has been appointed Scientific Director of the Sloan-Kettering Institute in New York , the world’s leading cancer research centre, which is part of the Memorial Sloan-Kettering Cancer Centre. The Catalan scientist has been chosen by an international expert committee and will take office on the 1^st of January 2014. The President and CEO of the Memorial Sloan-Kettering, Craig B. Thomson, said that Massagué had been given the job for his “exemplarity as a scientist” and because he is an “international leader” in the study of metastasis and factors regulating cell growth. This announcement follows last year’s appointment of another Catalan Doctor, Josep Baselga, as the Physician-in-Chief of the Memorial Sloan-Kettering Cancer Centre. Both Baselga and Massagué will continue to combine their responsibilities in New York with their research in Barcelona.

Researchers from Barcelona’s Centre for Regenerative Medicine (CMRB), the Catalan capital’s Hospital Clínic and the Salk Institute of California have successfully created three-dimensional renal structures which are virtually indistinguishable from embryonic kidneys. They have started creating kidney cells from human stem cells, and ultimately proven that these newly created cells could aggregate in vitro to form a “micro-kidney”. The team led by Juan Carlos Izpisúa, from the CMRB, said that this scientific breakthrough would facilitate the study of kidney diseases and enable scientists to work on new treatments. He added that this achievement was a great step towards developing therapies based on the use of stem cells.

The President of the Catalan Government, Artur Mas, has travelled to Israel heading a delegation including businesspeople as well as the Mayor of Barcelona, Xavier Trias, and the Catalan Minister for the Economy, Andreu Mas-Colell, among others. On Tuesday Mas met Shimon Peres, President of Israel, and on Monday the Finance Minister, Yair Lapid, who is also the Chairman of Yesh Atid (the second-largest party in the Knesset) and ‘number 2’ in Benjamin Netanyahu’s Government. With Peres, Mas talked about a federal European Union and Catalonia’s process of building its own state. With Lapid, who is a clearly emerging figure in Israel’s political landscape, Mas talked strictly about economic matters. The Catalan delegation also signed several agreements regarding scientific research and visited the Holocaust Memorial as well as the Wailing Wall.

The University of Lleida (Western Catalonia) will be leading the INNOSTORAGE Project regarding efficient thermal storage. They will focus their study on improving energy-storing by using Phase Change Materials and their temperature changes. The project, which is financed by the European Commission, aims at reducing CO2 emissions and saving energy by finding new efficient energy-storing systems. Thanks to the Marie Curie International Research Staff Exchange Scheme (IRSES), INNOSTORAGE brings together searchers from Catalonia, France, Israel, the United-States, Australia, and New-Zealand.